Kyprolis (Carfilzomib) for Myeloma

Overview
Kyprolis is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in people who have tried other therapies. Kyprolis is often combined with a corticosteroid and other drugs such as Revlimid in specific chemotherapy regimens to treat myeloma. Kyprolis may also be referred to by its drug name, carfilzomib.

Kyprolis is an anticancer drug used in chemotherapy. Kyprolis is a member of a class of drugs called proteasome inhibitors. Kyprolis is believed to work by interfering with cell division.

How do I take it?
Kyprolis is administered as an intravenous infusion.

Side effects
The FDA-approved label for Kyprolis lists common side effects including anemia, fatigue, fever, nausea, diarrhea, cough, cold or flu symptoms, trouble breathing, and swelling in the extremities.

Rare but serious side effects listed for Kyprolis include heart failure, kidney failure, tumor lysis syndrome, lung toxicity, hypertension, bleeding in the lungs, brain, or gastrointestinal system, and fetal harm in pregnant women.

For more details about this treatment, visit:

Kyprolis — Amgen
https://www.kyprolis.com

Drug Therapy for Multiple Myeloma — American Cancer Society
https://www.cancer.org/cancer/multiple-myeloma/...